Significant advances in genetics, pathology, biomarkers and endpoints are driving momentum in neuroscience drug discovery, from small molecules to advanced therapies. Charles River is committed to changing the course of neuroscience research, providing deep translational expertise as a trusted partner for preclinical models, innovative drug discovery, and IND-enabling studies.